Filer Snapshot

GLENVIEW CAPITAL MANAGEMENT, LLC

CIK 0001138995. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

69

Latest filing

16 Nov 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q3 2026. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Largest parsed holding

GPN

$580.3M reported value

Open holding

13D/G large stake

SGRY

06 Oct 2026 · 5.4% ownership

Open 13D/G
Source: SEC Schedule 13D/G

SCHEDULE 13G/A filed on 16 Nov 2026 for CIK 0001138995.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

13F portfolio$5.63B

Quarterly institutional holdings reported on Form 13F; not total AUM.

Latest reported 13F value

13F
$5.63B

Reported market value from the latest parsed Form 13F information table; this is not total assets under management.

Source: SEC Form 13FScope: U.S.-listed equity holdings

Largest 13F holdings

13F
GPN THC AMZN META TMO
+15 moreTEVA A AMD DHR HUM ONTO CNC UBER CI CVS BFLY GENI UAL SGRY BRKR

Largest symbols in the latest parsed Form 13F information table.

Freshness: Latest parsed 13F period

Largest 13F holdings

Largest symbols in the latest parsed Form 13F information table.

GPN THC AMZN META TMO TEVA A AMD
+12 moreDHR HUM ONTO CNC UBER CI CVS BFLY GENI UAL SGRY BRKR

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

BFLY

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

GTM ALIT DXC GENI SGRY MYGN
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
520 Madison Avenue, 33 Rd Floor, New York, NY, 10022
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
DE
Fiscal year end
31 December

Filer intelligence

What SEC filings say about GLENVIEW CAPITAL MANAGEMENT, LLC

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Quick read

  • Latest parsed 13F shows $5.63B across 135 reported holdings for Q3 2026.
  • Largest parsed 13F holding: GPN at $580.3M.
  • 5 recent 13D/G stake rows found; top row is SGRY at 5.4% ownership.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 135 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 5 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q3 2026 - 16 Nov 2026

Top 5 concentration

38%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$2.14B

Compared with $5.63B total 13F value.

Top 5 net change

-$162.5M

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: TEVA · Largest trim: CVS

GPN THC AMZN META TMO Other holdings

GPN

10.3%

Global Pmts Inc

$580.3M

THC

9.3%

Tenet Healthcare Corp

$523.35M

AMZN

6.6%

Amazon Com Inc

$372.6M

META

6.4%

Meta Platforms Inc

$359.16M

TMO

5.3%

Thermo Fisher Scientific Inc

$299.89M

13D/G large-stake context

SGRY

06 Oct 2026 · Common Stock, par value $0.01 per share

5.4%

GENI

30 Sep 2026 · Ordinary Shares

6.2%

BFLY

13 Aug 2026 · Class A common stock, par value $0.0001 per share

6.2%

MYGN

30 Jun 2026 · Common Stock, par value $0.01 per share

0%

Latest update

What changed recently for GLENVIEW CAPITAL MANAGEMENT, LLC

New filing available

Latest 13F period: Q3 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

16 Nov 2026

Page type

Filer profile

Latest period

Q3 2026

Institutional portfolio context was refreshed from a 13F filing filed on 16 Nov 2026.

Benchmark Context

Benchmark context for this company

GLENVIEW CAPITAL MANAGEMENT, LLC has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest 13F period: Q3 2026. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

SEC filing record

CIK 0001138995 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
69
First seen
14 Feb 2014
Latest filing
16 Nov 2026
Entity
Company

Observed form types

13F-HR 13F-HR/A SCHEDULE 13D/A SCHEDULE 13G SCHEDULE 13G/A

Latest Filings

Showing the latest 12 of 69 SEC filings for GLENVIEW CAPITAL MANAGEMENT, LLC.

SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
16 Nov 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
16 Nov 2026
Reporting date
30 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
13 Oct 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
17 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Aug 2026
Reporting date
30 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
21 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
15 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
27 Mar 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
17 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .